Cantor Fitzgerald Thinks Aimmune Therapeutics’ Stock is Going to Recover


In a report released today, Charles Duncan from Cantor Fitzgerald reiterated a Buy rating on Aimmune Therapeutics (AIMT), with a price target of $45. The company’s shares opened today at $22.33, close to its 52-week low of $20.94.

Duncan wrote:

“We reiterate our Overweight rating and PT of $45 per share on AIMT. Aimmune announced today that its P3 ARTEMIS study for AR101 in peanut allergy (PA) in the EU met its primary endpoint, a high-bar efficacy measure that we had seen as a non-zero risk. As a result, Aimmune is the only company to successful complete two P3 efficacy studies in PA, underscoring the efficacy of AR101 compared other products under development. Although details of the topline results are under an embargo agreement and were not disclosed, these will be presented at EAACI in June. Briefly, the proportion of AR101 treated patients who tolerated a 1000mg dose of peanut protein in a blinded exit food challenge after ~9 months of AR101 treatment was significantly higher (p<0.00001) compared to placebo."

According to TipRanks.com, Duncan is a 4-star analyst with an average return of 4.5% and a 51.2% success rate. Duncan covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co Ltd, Crinetics Pharmaceuticals Inc, and KalVista Pharmaceuticals Inc.

Aimmune Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $57.29, which is a 156.6% upside from current levels. In a report issued on March 19, Wedbush also maintained a Buy rating on the stock with a $76 price target.

See today’s analyst top recommended stocks >>

Based on Aimmune Therapeutics’ latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $57 million. In comparison, last year the company had a GAAP net loss of $41.17 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Aimmune Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of desensitization treatments for peanut and other food allergies. Its portfolio includes the characterized oral desensitization immunotherapy system. The company was founded on June 24, 2011 and is headquartered in Brisbane, CA.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts